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Abstract
Purpose: Recently, updated EARL specifications (EARL2) have been developed and
announced. This study aims at investigating the impact of the EARL2 specifications
on the quantitative reads of clinical PET–CT studies and testing a method to enable
the use of the EARL2 standards whilst still generating quantitative reads compliant
with current EARL standards (EARL1).
Methods: Thirteen non-small cell lung cancer (NSCLC) and seventeen lymphoma
PET–CT studies were used to derive four image datasets—the first dataset complying
with EARL1 specifications and the second reconstructed using parameters as
described in EARL2. For the third (EARL2F6) and fourth (EARL2F7) dataset in EARL2,
respectively, 6 mm and 7 mm Gaussian post-filtering was applied. We compared the
results of quantitative metrics (MATV, SUVmax, SUVpeak, SUVmean, TLG, and tumor-
to-liver and tumor-to-blood pool ratios) obtained with these 4 datasets in 55
suspected malignant lesions using three commonly used segmentation/volume of
interest (VOI) methods (MAX41, A50P, SUV4).
Results: We found that with EARL2 MAX41 VOI method, MATV decreases by 22%,
TLG remains unchanged and SUV values increase by 23–30% depending on the
specific metric used. The EARL2F7 dataset produced quantitative metrics best
aligning with EARL1, with no significant differences between most of the datasets
(p>0.05). Different VOI methods performed similarly with regard to SUV metrics but
differences in MATV as well as TLG were observed. No significant difference between
NSCLC and lymphoma cancer types was observed.
Conclusions: Application of EARL2 standards can result in higher SUVs, reduced
MATV and slightly changed TLG values relative to EARL1. Applying a Gaussian filter
to PET images reconstructed using EARL2 parameters successfully yielded EARL1
compliant data.
Keywords: Performance, Harmonisation, PET, CT, Quantification, EARL accreditation,
Standards
Introduction
Positron emission tomography (PET) and computed tomography (CT) hybrid imaging
(PET–CT) with 18F-fluorodeoxyglucose (18F-FDG) is widely being used in oncology for
diagnosis, staging, restaging and therapy response evaluation due to its ability to
measure metabolic changes [1–7]. In addition to visual inspection, quantitative PET
data analysis [8] can provide additional benefits such as increased precision and
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
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reduced inter-observer variability [9]. Standardised uptake value (SUV) is commonly
used to represent the tissue radioactivity concentration normalised to the whole body
activity concentration, estimated from injected activity and body weight [10]. However,
SUV bias and increased variability can arise from multiple factors [9, 11] and need to
be given extra consideration when multicentre data are desired or absolute quantitative
measures used [9, 12–15].
Therefore, several scientific societies such as the European Association of Nuclear
Medicine (EANM), American College of Radiology (ACR), American Association of
Physicists in Medicine (AAPM), Radiological Society of North America (RSNA) and
Society of Nuclear Medicine and Molecular Imaging (SNMMI) are promoting stand-
ardisation and harmonisation of imaging procedures and practices to reduce variability
of quantification in a multicentre setting [16–20]. Results and experience with these
programs are described in papers by Scheuermann et al. [19], Sunderland et al. [21]
and Kaalep et al. [22].
In 2006, EANM Research Ltd. (EARL) initiative was launched by the EANM to promote
multicentre nuclear medicine and research. In 2010, the EARL 18F-FDG-PET–CT ac-
creditation program was established to address variability in the quickly growing field of
quantitative 18F-FDG PET imaging by setting up guidelines and specifications to which
the participating sites must adhere. According to these guidelines, an accredited PET–CT
system, in addition to other requirements, has to display a SUV bias of ±10% or less and
produce contrast recoveries within a specified bandwidth (EARL1 and EARL2), when im-
aging hot spheres of various sizes within a NEMA NU2–2007 phantom.
The varying performance caused by multiple generations of PET–CT systems (2D,
3D acquisition, time-of-flight (TOF), etc.) and availability of various reconstruction
technologies (e.g. resolution recovery/point spread function (PSF) or Bayesian
penalised-likelihood reconstruction) pose a particular problem when harmonisation
within the community is desired. Multicentre standards should not be based on the
least performing systems. They need to fit with the highest, yet common, denominator
in systems’ performance.
The specifications for the EARL1 18F-FDG PET–CT accreditation program were
developed during a pilot study performed during 2010–2011, involving 12 PET–CT
systems. Since then, the performance of PET–CT systems has significantly increased
and new acquisition and reconstruction technologies have been introduced [23]. A
change in technology may also unfavourably affect patient management when previ-
ously used quantitative and visual criteria are applied without adaptation to the new
images [24, 25]. The harmonisation of these newer systems would require an update of
the current multicentre accreditation standards (EARL1) to accommodate higher recov-
eries. A phantom study by Kaalep et al. [26] showed that the harmonisation of modern
PET–CT systems from different vendors is feasible. Based on this study, the EARL1
specifications have been updated and EARL2 specifications were developed [26].
The introduction of an updated EARL standard changes quantitative PET–CT reads
and these changes should be known and/or accounted for. Moreover, for ongoing mul-
ticenter studies, it is advisable to continue generating data following the EARL1 stand-
ard to assure uniformity of image quantification for the entire multicenter dataset. The
latter may be challenging for imaging sites as it could imply that three reconstructions
are generated. One reconstruction following locally preferred settings optimised for
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lesion detectability, another reconstruction following EARL2 and a third recon-
struction following EARL1 standards. Therefore, it is of interest to explore if an
existing approach based on image filtering [27] can be applied to generate EARL1
compliant data from EARL2 reconstructed images. This would obviate the need to
perform a (third) EARL1-compliant reconstruction. Moreover, it would still allow
to generate both EARL2- and EARL1-compliant quantitative results to allow com-
parison of results with historic cohorts. Although in principle the image filtering
approach can be applied to the clinically preferred reconstructions to generate
either (or both) EARL1- or EARL2-compliant data, the filter settings required
would vary from one site to another as locally preferred reconstruction settings are
not the same. In a multicenter study, this would require that these filter settings
be derived, known and monitored for each system as this method does not gener-
ate EARL-compliant images. Yet, deriving EARL1-compliant data from EARL2 re-
constructed images is a more standardised condition or procedure and might be
more easily reproduced elsewhere.
The primary aim of the current study is to investigate the impact of EARL2 updated
accreditation specifications on the quantitative reads of clinical PET–CT studies. A sec-
ondary objective is to evaluate the performance of an (existing) approach based on
image filtering to generate quantitative reads that are compliant with the EARL1 stan-
dards from EARL2-compliant reconstructed PET images.
Materials and methods
Selecting post-filtering parameters by phantom experiments
Twenty-one phantom images from a previously described study by Kaalep et al. [26]
were investigated. These phantom images served to determine a post-filter which, when
applied to an EARL2-compliant dataset, would result in a dataset compliant with the
EARL1 standards. The data were collected from 17 EARL accredited scanners from
major vendors—3 Philips, 9 Siemens and 5 General Electric systems. The phantom
experiments were performed in compliance with EARL Image Quality QC standard
operating procedures. A NEMA NU2-2007 body phantom background was filled with a
2 kBq/ml 18F-FDG solution and the 10-, 13-, 17-, 22-, 28- and 37-mm spheres with a
20 kBq/ml 18F-FDG solution, resulting in a 10:1 sphere to background ratio when
scanned for two 5-min per bed positions. TOF, PSF, normalisation, randoms, scatter
and attenuation corrections were applied. Reconstructions compliant with EARL1 as
well as EARL2 specifications were performed. Reconstructed data were analysed using
a semi-automatic tool developed for EARL [16]. Further details regarding the acquisi-
tion of the phantom data can be found in the initial study [26].
An additional Gaussian post-filtering with kernel sizes of 5, 6, 7 and 8 mm, respect-
ively, was applied to the EARL2-compliant phantom datasets using in-house post-
processing and analysis software ACCURATE [28]. Size-dependent SUVmean and
SUVmax recovery coefficients of all resulting datasets were compared with the EARL1
accreditation specifications to determine which filter values provided the largest num-
ber of EARL1-compliant results. A dataset was determined to be EARL1 compliant
when observed contrast recoveries of SUVmean and SUVmax in all spheres were
within EARL1 specifications. This strategy and methodology is equal to the one
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proposed and evaluated by Lasnon et al. [27] and tested here to see if it could also be
applied to derive EARL1-compliant results from EARL2 reconstructed PET data.
Patient selection and preparation
Thirty patients with non-small cell lung cancer (NSCLC, n=13) or lymphoma (n=17)
were randomly selected from ongoing routine clinical staging or restaging studies with
suspected positive lesions. The majority of lymphoma patients were diagnosed with dif-
fuse large B-cell lymphoma. A standard uptake time of 60–75 min was applied to all
patients. Further details can be found in Table 1.
Acquisition and reconstruction parameters
30 patient scans performed on two EARL-accredited Philips Ingenuity PET–CT TOF
systems during a period of 2.5 years (from 10.03.2016 to 10.09.2018) were selected for
further analysis within this study. For each patient study, two PET reconstructions were
performed—first, using the EARL1-approved reconstruction parameters resulting in
contrast recoveries within EARL1 accreditation specifications [29], and second, using
the EARL2-compliant reconstruction parameters proposed by Kaalep et al [26]. Two
additional image datasets were generated from the EARL2-reconstructed images by ap-
plying Gaussian filters of 6.0 mm (EAR2F6) and 7.0 mm (EAR2F7), respectively. Main
parameters for the four PET image datasets used in this study are listed in Table 2.
Lesion selection, segmentation and analysis
Lesions suspected to be malignant were identified by the author (AK) and confirmed
by a certified nuclear medicine physician with 10 years of experience reading PET–CT
images (DO). Physiological 18F-FDG uptake (i.e. within brain, left ventricle, kidneys,
urinary bladder) not related to the primary disease was excluded. A maximum of 3
lesions per patient were selected to avoid over-representation of any single patient,
yielding a total of 55 lesions. VOIs were segmented semi-automatically using a region-
growing method with the following thresholds:
1. SUV ≥ 4.0 (SUV4).
2. 41% of SUVmax (41MAX).
3. 50% of SUVpeak with adaptation to local tumor-to-background contrast, so-called
adapted 50% of SUVpeak (A50P) [30]. SUVpeak is defined as the average uptake in
Table 1 Patient characteristics
Characteristics Non-small cell lung cancer Lymphoma Total
Total no. of patients 13 17 30
Males/females 6 / 7 10 / 7 16 / 14
Weight of patients (mean) 42 – 92 (69.4) kg 61 – 103 (78.9) kg 42 – 103 (74.8) kg
BMI of patients (mean) 18 – 28 (23.3) 19 – 41 (25.7) 18 – 41 (24.7)
Administered activity (mean) 161 – 314 (240) MBq 205 – 347 (274) MBq 161 – 347 (259) MBq
Total no. of analysed lesions 19 36 55
Lesions per patient (mean) 1-3 (1.5) 1-3 (2.1) 1-3 (1.8)
Kaalep et al. EJNMMI Physics            (2019) 6:28 Page 4 of 16
a 1.2-cm-diameter VOI positioned such to yield the highest value across all tumor
voxels (also referred to as highest peak) [31].
Additionally for each patient, liver and blood pool VOIs were created, and SUVmax,
SUVpeak and SUVmean calculated for EARL1, EARL2 and EARL2F7 reconstructions.
For assessing liver uptake, we positioned a 3-cm-diameter spherical VOI in the right
upper lobe of the (healthy) liver, as suggested by PERCIST [31]. For the blood pool up-
take, a 1.5-cm spherical VOI was positioned in the lumen of the ascending aorta.
For each combination of lesion, reconstruction and VOI threshold, the following
quantitative metrics were calculated: metabolic active tumor volume (MATV), SUV-
mean, SUVmax, SUVpeak and total lesion glycolysis (TLG) [30]. Moreover, we derived
tumor-to-liver ratios using SUVmax of both lesion and liver as well as SUVmax of the
lesion and SUVmean of the liver. Brief descriptions of the used VOI methods and
quantitative metrics are given in Table 3.
Statistical analyses
Median relative differences of quantitative metrics determined from EARL2, EARL2F6
and EARL2F7 reconstructions and corresponding values from the EARL1 reconstruc-
tion were reported along with interquartile ranges. Mann–Whitney U test and











EARL1 4 4 BLOB-OS-TF N/A OFF
EARL2 4 4 BLOB-OS-TF N/A ON
EARL2F6 4 4 BLOB-OS-TF 6.0 ON
EARL2F7 4 4 BLOB-OS-TF 7.0 ON
Table 3 Descriptions of used VOI methods and quantitative metrics
VOI methods Description
A50P Region-growing-based VOI using 50% of SUVpeak with adaptation to local
tumor-to-background contrast [32, 30]
SUV4 Region-growing-based VOI using a threshold of SUV equal to 4
MAX41 Region-growing-based VOI using a threshold equal to 41% of SUVmax
Quantitative metrics Description
MATV Volume of a lesion segmented using A50P, SUV4 or MAX41 method in mL
SUVmean Ratio of image-derived average radioactivity concentration within a region of
interest and the estimated whole body concentration of the injected radioactivity,
normalised to bodyweight
SUVmax Ratio of image-derived maximum (single pixel) radioactivity concentration within a
region of interest and the whole body concentration of the injected radioactivity,
normalised to bodyweight
SUVpeak Ratio of image-derived average radioactivity concentration within a 12-mm-diameter
spherical volume (taking into account fractional voxels) within the region of interest,
positioned to yield the highest uptake across all tumor voxel locations, and the whole
body concentration of the injected radioactivity, normalised to bodyweight [30, 31]
TLG Total lesion glycolysis equal to the MATV times SUVmean
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Wilcoxon signed-rank test were used to evaluate the statistical significance of the
paired and non-paired data, respectively.
Results
Phantom data
Post-filtering values of 6 and 7 mm resulted in the highest number of EARL2 recon-
structions (across all phantom scans) conforming to EARL1 specifications for both
SUVmean and SUVmax (Fig. 1) and were selected for further analysis and testing using
clinical datasets. As an example, Fig. 2 demonstrates the investigated systems’ contrast
recovery curves before and after the application of an additional 6-mm FWHM
Gaussian post-filter.
Clinical data
Figure 3 illustrates an example of a malignant lesion and the associated quantitative metrics
calculated. We found that EARL2 SUV data were higher than EARL1 data (p<0.001), the
relative median difference ranging from 23% for SUVpeak to 25% for SUVmean and 30%
for SUVmax (Table 4, Fig. 4c, d). The relative difference in SUV between the two datasets
increased with decreasing MATV (p<0.001) with a median difference of 36%, 39% and 25%
(SUVmax, SUVmean and SUVpeak, respectively) for small (< 10 ml) lesions and 22%, 21%
and 15% (SUVmax, SUVmean and SUVpeak, respectively) for large (≥ 10 ml) lesions (Fig.
4c), with no significant dependence on SUVmean, i.e. lesion contrast (SUVmax, p=0.162;
SUVmean, p=0.225; SUVpeak, p=0.178) (Fig. 4d). SUV data from the filtered dataset
EARL2F7 aligned best with those obtained using EARL1 reconstruction within -1% for
SUVmax (interquartile range 9.5), -1% for SUVmean (interquartile range 9.4) and +2% for
SUVmax (interquartile range 6.4).
MATV seen on the EARL2 was on average 27% smaller (p<0.001) when compared to
EARL1 (Table 4, Fig. 4a, b), while the difference reduced to a statistically non-significant
+2% (p=0.547) when EARL2F7 and EARL1 were compared. Results for the A50P and
SUV4 VOI methods can be found in the supplemental data (Additional file 5: Table S1
and Table S2). The relative difference in EARL2 and EARL1 MATV values was found to
be dependent on the underlying MATV values (p<0.001) with an average difference of
-31% for small (< 10 ml) lesions and -19% for large (≥ 10 ml) lesions (Fig. 4a). Significant
Fig. 1 Histogram of Gaussian post-filter values resulting in EARL1-compliant reconstructions of NEMA NU2-
2007 body phantom data acquired in accordance with EARL guidelines for Image Quality QC standard
operating procedures
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MATV dependence (p<0.001) remained when EARL2F7 and EARL1 were compared, with a
median difference of +6% for small (< 10 ml) lesions and -8% for large (≥ 10 ml) lesions. A
significant dependence of underlying SUV levels (p=0.033) was found in MATV differences
Fig. 2 Recovery coefficient values relative to sphere size determined from NEMA NU2-2007 body phantom data
acquired in accordance with EARL guidelines for Image Quality QC standard operating procedures. a SUVmean
of EARL2 and EARL2F6 data. b SUVmax of EARL2 and EARL2F6 data. Average measured EARL1 SUV data—solid
black line, average measured EARL2F6 SUV data—solid red line current, standard deviation from average
measured EARL1 SUV data—black dash dot dot line; standard deviation from average measured EARL2F6 SUV
data—red dash dot dot line; EARL standard—bold black lines, prospective future EARL standard—bold red lines
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Fig. 3 Typical example image of a lymphoma patient’s 18F-FDG PET–CT scan. Coronal maximum intensity
projection image is presented with an arrow pointing to a suspected malignant lesion along with the
corresponding MATV, SUVmax, SUVpeak, SUVmean and TLG quantitative metrics determined using EARL1,
EARL2, EARL2F6 and EARL2F7 reconstructions
Table 4 MAX41 VOI method relative median differences (%) of MATV, SUV metrics and TLG to
corresponding values of EARL1 reconstruction along with 25th and 75th percentiles. Values
marked with * indicate that the difference is statistically significant (p < 0.05)
Cancer
type
















18* (12/22) 29* (23/35)
EARL_V2F6 0 (-6/2) 3* (1/6) 5* (4/7) 3* (2/6) 2
(-1/4)
N/A N/A
EARL_V2F7 9 (1/14) -3 (-8/0) 1 (-2/3) -2 (-7/0) 4
(-2/8)









26* (14/30) 35* (22/41)
EARL_V2F6 -7* (-12/-2) 6* (2/13) 6* (3/11) 6* (0/12) 0
(-4/4)
N/A N/A
EARL_V2F7 0 (-5/7) 0 (-4/4) 2 (-2/4) 0 (-4/4) 0
(-5/5)













22* (14/29) 34* (23/39)
EARL_V2F6 -5*
(-11/1)
5* (1/11) 5* (3/9) 5* (2/9) 1
(-3/4)
N/A N/A
EARL_V2F7 2 (-4/11) -1 (-6/4) 2* (-2/4) -1 (-5/4) 2
(-4/7)
6* (1/9) -1 (-6/3)
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of EARL2 and EARL1, where lesions with SUVmean ≤ 7.0 demonstrated a median difference
of -29% while lesions with SUVmean > 7.0 demonstrated a median difference of -20%. Differ-
ences in MATV of EARL2F7 to EARL1 were independent (p=0.076) on underlying SUV
levels (Fig. 4b).
We found a statistically significant (p=0.005) difference of -2% in median TLG values
of EARL1 and EARL2 while no statistically significant difference in TLG derived from
EARL1 and EARL2F7 (p=0.744) or EARL1 and EARL2F6 (p=0.815).
Figure 5 demonstrates the differences in SUV in liver and blood pool VOIs between
EARL1 and EARL2 and EARL2F7 reconstructions. The largest difference can be seen with
SUVmax while SUVmean demonstrates the smallest change. Figure 6 visualises tumor-to-
liver ratio’s calculated using various combinations of SUV metrics. Additional results
comparing EARL2 and EARL2F7 reconstructions can be found in the supplemental data
(Additional file 2: Figure S2; Additional file 3: Figure S3; Additional file 4: Figure S4).
Tumor-to-liver ratio was significantly higher for EARL2 when either SUVmax (p<0.001)
or SUVmean (p<0.001) was used to measure liver SUV (Table 4). For EARL2F7, the dif-
ference with EARL1 data was still statistically significant (p<0.001) when SUVmax was
used to measure liver SUV and non-significant (p=0.344) when liver SUVmean was used.
All investigated metrics changed similarly between EARL2, EARL2F6 and EARL2F7
Fig. 4 Relative differences of 41MAX VOI method EARL2 and EARL2F7 reconstructions’ MATV, SUVmax and
TLG metrics compared to respective values from EARL1 reconstruction, presented as functions of EARL1
MATV and SUVmean. EARL2 reconstruction—red markers; EARL2F7 reconstruction—blue markers
Kaalep et al. EJNMMI Physics            (2019) 6:28 Page 9 of 16
reconstructions regardless of cancer type (Fig. 7). SUVmax and SUVpeak metric changes
remained similar while SUVmean, MATV and TLG behaviour differed based on the VOI
method used (Additional file 1: Figure S1). These differences between VOI methods were
eliminated in the EARL2F7 reconstruction (Additional file 1: Figure S1).
Discussion
Application of the updated EARL2 standards will affect quantitative reads. Yet, an up-
date of the current EARL1 standards is required to cope with new PET–CT technolo-
gies providing enhanced lesion detectability. In this paper, we studied the impact of
using EARL2 standards on the quantitative reads of NSCLC and lymphoma 18F-FDG
PET–CT studies as compared to the EARL1 standards. An (existing) image filtering ap-
proach that enables the use of updated EARL2-compliant reconstruction, whilst still
generating EARL1-compliant quantitative reads, was derived and tested. The latter is
Fig. 5 Relative differences of 41MAX VOI method EARL2 and EARL2F7 reconstructions’ liver and blood pool
SUVmean, SUVmax and SUVpeak metrics compared to respective values from EARL1 reconstruction, presented
as functions of EARL1 SUVmean. EARL2 reconstruction—red markers, EARL2F7 reconstruction—blue markers
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important to allow comparison of data during ongoing studies and/or for comparison
with historical cohorts.
As previously shown in the phantom study by Kaalep et al. [26], EARL2-compliant
reconstruction resulted in a significant increase in contrast recovery and higher SUVs.
The current study confirms these findings for clinical data (Table 4) and demonstrates
that overall trends (Table 4, Fig. 7) were similar for both lung cancer and lymphoma
Fig. 6 Relative differences of 41MAX VOI method EARL2 and EARL2F7 reconstructions’ tumor-to-liver ratios
compared to respective values from EARL1 reconstruction, presented as functions of EARL1 MATV and
SUVmean. a Tumor SUVmax to liver SUVmax ratio relative to MATV; b tumor SUVmax to liver SUVmax ratio
relative to SUVmean; c tumor SUVmax to liver SUVmean ratio relative to MATV; d tumor SUVmax to liver
SUVmean ratio relative to SUVmean; e tumor SUVpeak to liver SUVpeak ratio relative to MATV; f tumor
SUVpeak to liver SUVpeak ratio relative to SUVmean; g tumor SUVmean to liver SUVmean ratio relative to
MATV; h tumor SUVmean to liver SUVmean ratio relative to SUVmean; EARL2 reconstruction—red markers,
EARL2F7 reconstruction—blue markers
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patients despite different lesion sizes and tracer uptake levels (or SUV). This suggests
that the results of the current study could be universally applicable regardless of under-
lying disease type but this should be further investigated in future studies covering a
wider range of patients and conditions.
Increase in contrast in EARL2-compliant reconstructions is similar for the most com-
monly used metrics SUVmax and SUVpeak applying all investigated VOI methods
(Additional file 1: Figure S1) and is independent of the lesion contrast (SUVmean).
However, the results demonstrate a dependence on lesion volume where smaller lesions
show a larger increase in contrast. The overall increased contrast recovery explains the
wider and generally more preferred use of PSF reconstructions [23].
Fig. 7 Comparison of relative differences of MATV (a), SUVmax (b), SUVmean (c), SUVpeak (d), TLG (e) and
tumor-to-liver ratio (tumor SUVmax relative to liver SUVmean) (f) metrics between EARL1 and EARL2, EARL2F6,
and EARL2F7 reconstructions, respectively, using 41MAX VOI method. Results obtained from lung cancer and
lymphoma patients are presented separately. Central line of the box is the median, edges of the box are the
25th and 75th percentiles, the whiskers extend to either of the most extreme data points, which are not
considered outliers or 1.5 times interquartile range. The outliers are marked using plus signs
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EARL2-compliant reconstructions result in a significant reduction in MATV values
when MAX41 VOI method is used. Small (< 10 ml) lesions demonstrate a relatively
higher decrease in volume than larger (≥ 10 ml) lesions. At the same time, smaller le-
sions demonstrate larger increase in all SUV metrics which could be explained by the im-
proved resolution and reduced spill-out effect caused by the PSF reconstruction. Post-
filtering of the EARL2F6 and EARL2F7 reconstructions mimics the spill-out effect as the
image is blurred by the filter resulting in loss of resolution and dispersion of measured ac-
tivity in a larger volume. These results should not be transferred to other VOI methods as
the PSF reconstruction affects different lesion segmentation methods differently.
TLG did not change significantly among the four investigated reconstructions. This
may have been expected since while the lesion contrast (SUVmean) increases, MATV
decreases proportionally, resulting in a reduced change in the product of the two. This
reconstruction-independent behaviour of TLG could potentially make it a good metric
for generating consistent quantitative measurements from both EARL1 and EARL2
standards without further image modification. This is in agreement with Armstrong
et al., who suggested that TLG may be less sensitive to reconstruction methods com-
pared with either SUVmax or SUVpeak [33]. TLG could also reduce the uncertainty of
quantitative measurements of PET–CT scans that are performed on a system with un-
known recovery coefficients. These results should not be transferred to SUV4 VOI
methods as the PSF reconstruction affects the different lesion segmentations and,
therefore, the corresponding TLG values also.
EARL1-compliant quantitative results can be generated from EARL2-reconstructed
data using a simple filter. This approach has been applied and validated before by Las-
non et al., specifically for PSF reconstruction on a Siemens Biograph PET–CT system
using the so-called EQ.PET approach [27]. The method could, however, be considered
limited due to lack of similar solutions by other major vendors. Moreover, the appro-
priate filter for each PET–CT system is not reported in the DICOM header and thereby
the method cannot be applied offline or by 3rd party software. In our paper, we identi-
fied (from phantom experiments) and verified the appropriate Gaussian filter setting to
use EARL2-compliant reconstructions, while enabling the generation of EARL1 quanti-
tative results. Also, it is important for the verification of new datasets to be equivalent
to historical cohorts. In this way, data can be easily generated to conform to both
EARL1 and EARL2 standards without a need for additional reconstructions. For on-
going studies, however, it is recommended to keep adherence to the EARL1 standard
and optionally adding EARL2-compliant reconstructions to gain understanding of
quantitative implications when transitioning to the new standard.
It has been demonstrated by Kuhnert et al. that the increase in SUV, brought about
by the use of PSF reconstruction, remains significant even after normalisation to the
liver [24]. In our study, we also found that normalising lesion uptake to either liver
SUVmax or liver SUVmean resulted in significantly increased tumor-to-liver ratios and
confirm the results of Kuhnert et al that normalising to liver uptake does not mitigate
the effect of using different reconstructions on lesion uptake assessments. Apart from
harmonising quantitative 18F-FDG PET–CT reads, it has been reported that also visual
assessment, e.g. Deauville scoring of PET–CT lymphoma studies, may be affected by a
change in (reconstruction) technology and could affect patient management [25]. The
observed changes (increases) in tumor-to-liver ratios for EARL2- versus EARL1-
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compliant data suggest that the use of EARL2 standards will result in overall higher
Deauville scores, similarly as recently found by Ly et al. [34]. Therefore, it is not recom-
mended to change standards and/or use new technologies without properly (re-)defin-
ing interpretation criteria. Hence, use of EARL2-compliant reconstruction in combination
with generating a second filtered dataset could be helpful in recalibrating these criteria for
studies performed to conform EARL1 performance standards to those obtained using up-
dated performance standards. However, it should be noted that although this filtering ap-
proach has been shown to yield EARL1-compliant results and may facilitate these type of
studies, this has not yet been demonstrated in this study nor was the aim.
Conclusions
Multicentre clinical trials require standardisation of quantitative results to be usable
and exchangeable. This can be challenging as new acquisition and reconstruction tech-
nologies emerge and enable great benefits in image quality, but at the same time cause
the quantitative performance to diverge.
In this paper we studied the impact of using updated EARL2 standards on the quanti-
tative reads of NSCLC and lymphoma 18F-FDG PET–CT studies as compared to the
EARL1 standards. In general, the new EARL2 guidelines resulted in higher SUVs,
smaller MATV and similar TLG values. A 7-mm FWHM Gaussian filter was shown to
convert EARL2-compliant PET data to EARL1-compliant images. This facilitates the
generation of both new and existing EARL-compliant quantitative reads from a single
EARL2-compliant image reconstruction.
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Additional file 1: Figure S1. Comparison of relative differences of MATV (a), SUVmax (b), SUVmean (c), SUVpeak (d),
TLG (e) and tumor-to-liver ratio (tumor SUVmax relative to liver SUVmean) (f) metrics between EARL1 and EARL2,
EARL2F6, and EARL2F7 reconstructions, respectively, using different VOI methods. Central line of the box is the median,
edges of the box are the 25th and 75th percentiles, the whiskers extend to either of the most extreme data points,
which are not considered outliers or 1.5 times interquartile range. The outliers are marked using plus signs.
Additional file 2: Figure S2. Relative differences of A50P VOI method EARL2 and EARL_V2F7 reconstructions’
MATV, SUVmax and TLG metrics compared to respective values from EARL1 reconstruction, presented as functions
of EARL1 MATV and SUVmean. EARL2 reconstruction—red markers, EARL2F7 reconstruction—blue markers.
Additional file 3: Figure S3. Relative differences of SUV4 VOI method EARL2 and EARL2F7 reconstructions’
MATV, SUVmax and TLG metrics compared to respective values from EARL1 reconstruction, presented as functions
of EARL1 MATV and SUVmean. EARL2 reconstruction—red markers, EARL2F7 reconstruction—blue markers.
Additional file 4: Figure S4. Relative differences of 41MAX VOI method EARL2 and EARL2F7 reconstructions’
tumor-to-bloodpool ratio compared to respective values from EARL1 reconstruction, presented as functions of
EARL1 MATV and SUVmean. a tumor SUVmax to bloodpool SUVmax ratio relative to MATV; b tumor SUVmax to
bloodpool SUVmax ratio relative to SUVmean; c tumor SUVmax to bloodpool SUVmean ratio relative to MATV; d
tumor SUVmax to bloodpool SUVmean ratio relative to SUVmean; e tumor SUVpeak to bloodpool SUVpeak ratio
relative to MATV; f tumor SUVpeak to bloodpool SUVpeak ratio relative to SUVmean; g tumor SUVmean to blood-
pool SUVmean ratio relative to MATV; h tumor SUVmean to bloodpool SUVmean ratio relative to SUVmean; EARL2
reconstruction—red markers, EARL2F7 reconstruction—blue markers.
Additional file 5: Table S1. A50P VOI method relative median differences (%) of MATV, SUV metrics and TLG to
corresponding values of EARL1 reconstruction along with corresponding interquartile ranges. Values marked with *
indicate that the difference is statistically significant (p < 0.05). Table S2. SUV4 VOI method relative median differences
(%) of MATV, SUV metrics and TLG to corresponding values of EARL1 reconstruction along with corresponding
interquartile ranges. Values marked with * indicate that the difference is statistically significant (p < 0.05).
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